Assignee
QUARK PHARMACEUTICALS INC
US·40 granted patents·16 pending applications·419 citations·filing 2005–2018
Top patents by PatentIndex Score
56 records- 0199US7626015B2Therapeutic uses of inhibitors of RTP801LQUARK PHARMACEUTICALS INC·Filed 2007·Granted Dec 1, 2009·113 cites·6 claims
- 0298US7741299B2Therapeutic uses of inhibitors of RTP801QUARK PHARMACEUTICALS INC·Filed 2005·Granted Jun 22, 2010·107 cites·12 claims
- 0397US7825099B2Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genesQUARK PHARMACEUTICALS INC·Filed 2007·Granted Nov 2, 2010·24 cites·14 claims
- 0495US9932578B2Double-stranded oligonucleotide molecules to P53 and methods of use thereofQUARK PHARMACEUTICALS INC·Filed 2013·Granted Apr 3, 2018·31 cites·9 claims
- 0595US7910566B2Prevention and treatment of acute renal failure and other kidney diseases by inhibition of p53 by siRNAQUARK PHARMACEUTICALS INC·Filed 2008·Granted Mar 22, 2011·20 cites·5 claims
- 0693US7812002B2Oligoribonucleotide inhibitors of NRF2 and methods of use thereof for treatment of cancerQUARK PHARMACEUTICALS INC·Filed 2008·Granted Oct 12, 2010·21 cites·24 claims
- 0792US9121020B2Methods for treating eye disordersQUARK PHARMACEUTICALS INC·Filed 2014·Granted Sep 1, 2015·20 cites·23 claims
- 0890US8017764B2Therapeutic uses of inhibitors of RTP801LQUARK PHARMACEUTICALS INC·Filed 2009·Granted Sep 13, 2011·10 cites·8 claims
- 0990US7842674B2Methods of treatment of acute renal failureQUARK PHARMACEUTICALS INC·Filed 2007·Granted Nov 30, 2010·14 cites·25 claims
- 1089US7872119B2Inhibitors of RTP801 and their use in disease treatmentQUARK PHARMACEUTICALS INC·Filed 2008·Granted Jan 18, 2011·11 cites·13 claims
- 1186US9446062B2Methods of treating ischemia-reperfusion injury with siRNAsQUARK PHARMACEUTICALS INC·Filed 2015·Granted Sep 20, 2016·4 cites·14 claims
- 1285US7973156B2Hypoxia-regulated genesQUARK PHARMACEUTICALS INC·Filed 2008·Granted Jul 5, 2011·4 cites·3 claims
- 1385US7749977B2Therapeutic modulation of the Fas pathwayQUARK PHARMACEUTICALS INC·Filed 2006·Granted Jul 6, 2010·6 cites·5 claims
- 1482US8362229B2Tandem siRNASQUARK PHARMACEUTICALS INC·Filed 2007·Granted Jan 29, 2013·6 cites·25 claims
- 1581US9701961B2Methods for treating eye disordersQUARK PHARMACEUTICALS INC·Filed 2015·Granted Jul 11, 2017·3 cites·20 claims
- 1681US7524935B2Sequences characteristic of hypoxia-regulated gene transcriptionQUARK PHARMACEUTICALS INC·Filed 2006·Granted Apr 28, 2009·1 cites·10 claims
- 1780US9993567B2Composition of anti-ENDO180 antibodies and methods of use for the treatment of cancer and fibrotic diseasesQUARK PHARMACEUTICALS INC·Filed 2015·Granted Jun 12, 2018·2 cites·11 claims
- 1880US8614311B2RTP801L siRNA compounds and methods of use thereofQUARK PHARMACEUTICALS INC·Filed 2012·Granted Dec 24, 2013·2 cites·19 claims
- 1976US9434946B2Combination therapy for treating hearing and balance disordersQUARK PHARMACEUTICALS INC·Filed 2015·Granted Sep 6, 2016·2 cites·17 claims
- 2076US7939652B2Oligoribonucleotides and methods of use thereof for treatment of fibrotic conditions and other diseasesQUARK PHARMACEUTICALS INC·Filed 2008·Granted May 10, 2011·2 cites·16 claims
- 2175US10421962B2Double-stranded oligonucleotide molecules to DDIT4 and methods of use thereofQUARK PHARMACEUTICALS INC·Filed 2017·Granted Sep 24, 2019·1 cites·6 claims
- 2273US9611474B2Double-stranded oligonucleotide molecules to DDIT4 and methods of use thereofQUARK PHARMACEUTICALS INC·Filed 2013·Granted Apr 4, 2017·1 cites·20 claims
- 2373US9249414B2Oligonucleotide compounds comprising non-nucleotide overhangsQUARK PHARMACEUTICALS INC·Filed 2014·Granted Feb 2, 2016·1 cites·20 claims
- 2472US9422560B2Methods and compositions for neuroprotectionQUARK PHARMACEUTICALS INC·Filed 2012·Granted Aug 23, 2016·1 cites·14 claims
- 2572US9334499B2Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseasesQUARK PHARMACEUTICALS INC·Filed 2014·Granted May 10, 2016·1 cites·5 claims
- 2672US7723052B2Screening systems utilizing RTP801QUARK PHARMACEUTICALS INC·Filed 2007·Granted May 25, 2010·3 cites·18 claims
- 2771US9822362B2Compositions and methods for treating lung disease and injuryQUARK PHARMACEUTICALS INC·Filed 2015·Granted Nov 21, 2017·1 cites·19 claims
- 2871US9701960B2siRNA compounds comprising terminal substitutionsQUARK PHARMACEUTICALS INC·Filed 2014·Granted Jul 11, 2017·1 cites·18 claims
- 2971US8344104B2Screening systems utilizing RTP801QUARK PHARMACEUTICALS INC·Filed 2011·Granted Jan 1, 2013·1 cites·5 claims
- 3071US8034902B2Recombinant antibodies against CD55 and CD59 and uses thereofQUARK PHARMACEUTICALS INC·Filed 2006·Granted Oct 11, 2011·3 cites·14 claims
- 3169US8034575B2Screening systems utilizing RTP801QUARK PHARMACEUTICALS INC·Filed 2010·Granted Oct 11, 2011·1 cites·18 claims
- 3265US9382542B2Double-stranded RNA compounds to CASP2 and uses thereofQUARK PHARMACEUTICALS INC·Filed 2013·Granted Jul 5, 2016·1 cites·10 claims
- 3364US2009264634A1Sequences characteristic of hypoxia-regulated gene transcriptionQUARK PHARMACEUTICALS INC·Filed 2008·Application pending·0 cites
- 3460US2008300208A1Isociatrate dehydrogenase and uses therofQUARK PHARMACEUTICALS INC·Filed 2008·Application pending·0 cites
- 3558US2017226519A1METHODS OF TREATING ISCHEMIA-REPERFUSION INJURY WITH siRNASQUARK PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 3656US2013190387A1Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genesQUARK PHARMACEUTICALS INC·Filed 2013·Application pending·0 cites
- 3756US2009042826A1Use of the AXL receptor for diagnosis and treatment of renal diseaseQUARK PHARMACEUTICALS INC·Filed 2008·Application pending·0 cites
- 3856US2015065559A1METHODS FOR DELIVERY OF siRNA TO THE SPINAL CORD AND THERAPIES ARISING THEREFROMQUARK PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 3955US10494631B2siRNA compounds comprising terminal substitutionsQUARK PHARMACEUTICALS INC·Filed 2017·Granted Dec 3, 2019·0 cites·2 claims
- 4055US2009202566A1Use of the ENDO-180 gene and polypeptide for diagnosis and treatmentQUARK PHARMACEUTICALS INC·Filed 2008·Application pending·0 cites
- 4155US2017306329A1Methods for treating eye disordersQUARK PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
- 4253US9796979B2Oligonucleotide modulators of the toll-like receptor pathwayQUARK PHARMACEUTICALS INC·Filed 2016·Granted Oct 24, 2017·0 cites·10 claims
- 4353US9738896B2Methods and compositions for neuroprotectionQUARK PHARMACEUTICALS INC·Filed 2016·Granted Aug 22, 2017·0 cites·13 claims
- 4452US2011251260A1NOVEL siRNAS AND METHODS OF USE THEREOFQUARK PHARMACEUTICALS INC·Filed 2011·Application pending·0 cites
- 4550US9868953B2Methods and compositions for preventing ischemia reperfusion injury in organsQUARK PHARMACEUTICALS INC·Filed 2017·Granted Jan 16, 2018·0 cites·27 claims
- 4648US9611473B2Double-stranded nucleic acid compoundsQUARK PHARMACEUTICALS INC·Filed 2013·Granted Apr 4, 2017·0 cites·19 claims
- 4748US2016333357A1METHODS FOR DELIVERY OF siRNA TO THE SPINAL CORD AND THERAPIES ARISING THEREFROMQUARK PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 4848US2014364484A1Combination therapy for treating hearing and balance disordersQUARK PHARMACEUTICALS INC·Filed 2013·Application pending·0 cites
- 4947US10781449B2Double-stranded oligonucleotide molecules targeting p53 and methods of use thereofQUARK PHARMACEUTICALS INC·Filed 2018·Granted Sep 22, 2020·0 cites·11 claims
- 5047US2013030034A9Modulation of timp1 and timp2 expressionQUARK PHARMACEUTICALS INC·Filed 2011·Application pending·0 cites
Showing the top 50 of 56 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when QUARK PHARMACEUTICALS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →